West Pharma (NYSE: WST) reported Q2 EPS of $2.11, $0.17 better than the analyst estimate of $1.94. Revenue for the quarter came in at $753.8 million versus the consensus estimate of $757.43 million.

Full-year 2023 adjusted-diluted EPS is expected to be in a range of $7.65 to $7.80, compared to prior guidance range of $7.50 to $7.65.

Full-year adjusted-diluted EPS guidance range includes an estimated tailwind of approximately $0.05 based on current foreign currency exchange rates, compared to prior guidance of $0.02.
The updated guidance also includes EPS of $0.26 associated with first-half 2023 tax benefits from stock-based compensation.
For the second half of the year, our EPS guidance range assumes a tax rate of 22% and does not include potential tax benefits from stock-based compensation. Any tax benefits associated with stock-based compensation beyond those recorded in the first-half 2023 would provide a positive adjustment to our full-year adjusted-diluted EPS guidance.

For earnings history and earnings-related data on West Pharma (WST) click here.